【VAXIMM-Product VXM01】VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

Date:
2019-03-05
Category:
Partner News

5th March 2019 – Helius Medical Technologies, Inc. issued an announcement, which is
summarized as follows

We are excited to announce the treatment of the first patients
in Canada with our PoNS
? device, signifying Helius’ transition to a
commercial stage company.” said Philippe Deschamps, Helius’ Chief Executive
Officer.

The original website link

https://heliusmedical.com/index.php/newsroom/news-release/2019/268-